Ico Therapeutics, Inc. Stock Price - ICOTF

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Ico Therapeutics, Inc. (QB) ICOTF OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.0015 -2.34% 0.0625 0.068 0.0625 0.068 0.064 14:02:35
Bid Price Ask Price Spread Spread % News
0.0632 0.0724 0.0092 12.71% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
5 25,000 $ 0.068 $ 1,700 42,722 0.029 - 0.114
Last Trade Time Type Quantity Stock Price Currency
09:30:03 500 $ 0.0625 USD

Ico Therapeutics, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 6.84M 109.46M $ -1.70M - - 103.45M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
10.00k $ - 0.00% - -

more financials information »

Ico Therapeutics, Inc. News

Loading Messages....

Latest ICOTF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ICOTF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.071350.0770.06250.064396131,214-0.00885-12.4%
1 Month0.100.100.05690.077492299,786-0.0375-37.5%
3 Months0.06140.1140.05690.081315779,6930.00111.79%
6 Months0.0480.1140.0410.080156358,9210.014530.21%
1 Year0.05890.1140.0290.077039535,8840.00366.11%
3 Years0.030.20350.020.074578231,2550.0325108.33%
5 Years0.03670.20350.01110.047581951,0710.025870.3%

Ico Therapeutics, Inc. Description

iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company holds worldwide rights to an oral drug delivery platform, with Oral Amphotericin B (Amp B) as the initial platform candidate, utilizing a known anti-fungal drug to treat life-threatening infectious diseases. Oral Amp B has completed a Phase 1 clinical trial. iCo also has worldwide rights to iCo-008, a monoclonal antibody targeting eotaxin-1. With Phase 2 clinical history, Bertilimumab (iCo-008) is candidate for the treatment of vernal or atopic keratoconjunctivitis and Bullous Pemphigoid.

Your Recent History
Ico Therap..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.